STOCK TITAN

Insider Steve Meyers plans 6,864-share OCUL (NASDAQ: OCUL) sale

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

Ocular Therapeutix insider Steve Meyers has filed a Form 144 to sell 6,864 shares of common stock. The shares are planned to be sold through Morgan Stanley Smith Barney LLC on or about February 12, 2026, with an indicated aggregate market value of $62,034.09.

The 6,864 shares were acquired on February 11, 2026 through restricted stock vesting under a registered plan. Over the past three months, Meyers has already sold 4,408 shares for $37,636.39 and 3,052 shares for $27,903.83. Shares outstanding were 217,691,779 at the time referenced.

Positive

  • None.

Negative

  • None.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What does the OCUL Form 144 filing by Steve Meyers disclose?

The Form 144 shows Steve Meyers’ intention to sell 6,864 OCUL common shares. These shares were recently acquired through restricted stock vesting, and the planned sale will be executed through Morgan Stanley Smith Barney LLC, subject to Rule 144 conditions and market execution.

How many OCUL shares does Steve Meyers plan to sell under this Form 144?

Steve Meyers plans to sell 6,864 OCUL common shares. The filing lists an aggregate market value of $62,034.09 for this block, based on the market price at the time the notice was prepared for the anticipated sale date.

When were the OCUL shares in the Form 144 acquired and how?

The 6,864 OCUL shares were acquired on February 11, 2026. They came from restricted stock vesting under a registered compensation plan, with the issuer as the source, and no separate cash payment noted for this acquisition in the filing.

What prior OCUL stock sales by Steve Meyers are reported in the last 3 months?

The filing reports two recent OCUL stock sales by Steve Meyers. He sold 4,408 common shares on February 4, 2026 for $37,636.39 and 3,052 common shares on February 2, 2026 for $27,903.83, all within the three months before this notice.

How many OCUL shares were outstanding at the time of the Form 144 reference?

The notice lists 217,691,779 OCUL common shares outstanding. This figure provides context for the relative size of the 6,864-share proposed sale, but it does not change or register the total outstanding shares itself.

Through which broker will the planned OCUL share sale be executed?

The proposed sale of 6,864 OCUL shares is to be executed through Morgan Stanley Smith Barney LLC. The filing specifies its Executive Financial Services group at 1 New York Plaza, 8th Floor, New York, NY 10004 as the broker handling the transaction.
Ocular Therapeut

NASDAQ:OCUL

View OCUL Stock Overview

OCUL Rankings

OCUL Latest News

OCUL Latest SEC Filings

OCUL Stock Data

1.85B
210.88M
Biotechnology
Pharmaceutical Preparations
Link
United States
BEDFORD